Fig. 7
Long-term protective memory immune responses elicited by DEXP&A&N and Flt3L against tumor re-challenge. Flow cytometric and quantitative analysis of CD44hi CD8+ (a) and CD62LlowCD44hiCD8+ (b) T cells in blood of orthotopic HCC mice treated with PBS (n = 4), DEXP&A&N, DEXP&A&N and Flt3L (n = 6) at day 42 after tumor implantation (one-way ANOVA post hoc Student–Newman–Keuls test). c Diagram for tumor re-challenge in DEXP&A&N and Flt3L-treated tumor-free mice. d Measurement of tumor volume in DEXP&A&N and Flt3L-treated tumor-free mice after re-challenge (n = 4). Mann–Whitney rank-sum test was used for day 7; one-way ANOVA on ranks test was used for day 14, 21, 28, 35 and 42; one-way ANOVA post hoc Student–Newman–Keuls test was used for day 49. e Survival rate of DEXP&A&N and Flt3L-treated tumor-free mice after re-challenge (n = 4). Flow cytometric and quantitative analysis of CD44hiCD8+ (f) and CD62LlowCD44hi CD8+ (g) T cells in blood of DEXP&A&N and Flt3L-treated tumor-free mice at different time points after tumor re-challenge (n = 4; one-way ANOVA post hoc Student–Newman–Keuls test). *p < 0.05, **p < 0.001; n.s, not significant